OH-PROAMPAC
1.5.2023 16:18:28 CEST | Business Wire | Press release
ProAmpac, a leader in flexible packaging and material science, will showcase its products at Interpack, a worldwide exhibition for the packaging industry, in Hall 10, Stand D21. The event is scheduled to take place in Dusseldorf, Germany, from 4-10 May.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230501005442/en/
ProActive Recyclable R-2050 is a high-performance mono PE recyclable film that features superior heat resistance, excellent directional tear for easy opening and various barrier properties available to suit even the most sensitive products. (Photo: Business Wire)
"We're thrilled to be back at Interpack this year with sustainable packaging innovation and our expanded capabilities in Europe, Ireland, and the UK. Our recent additions, such as digital printing, spouted and aseptic pouching, and our commitment to ESG goals, enable us to collaborate on the latest innovations in flexible packaging," states Adam Grose, chief commercial officer for ProAmpac.
Sustainable Packaging Innovations
ProAmpac will showcase its sustainable offerings with its ProActive Sustainability® line of packaging. New product innovations on display include:
- ProActive Recyclable R-2050. This high-performance mono PE recyclable film features superior heat resistance, excellent directional tear for easy opening and various barrier properties available to suit even the most sensitive products.
- QUADLFEX Recyclable is a film-based quad packaging solution that is perfect for high-speed filling lines. This packaging can be customized with clear windows and surface finishes and is preapproved for recycling through the in-store drop-off program.
- ProActive Recyclable RP-1000, a recyclable paper-based product that provides barrier protection for dry and non-greasy food products.
- PRO-EVO Recyclable provides excellent grease and edge-wicking resistance without intentionally adding per- and poly-fluoroalkyl substances (PFAS). PRO-EVO Recyclable is also available with a high moisture barrier to maintain the freshness of pet foods.
- RAP Packaging Products keeps food to-go fresh and offers an elevated appearance in either a hot cabinet or a chiller. Also, by weight, the largest packaging component is paperboard and paper sourced from well-managed forests, which is widely recyclable in fibre streams. ProAmpac’s food to-go packaging solutions are 2023 OPRL 90/10 compliant.
- ProActive PIR film contains 30% polyethylene-based postindustrial recycled content, meets UK Plastic Packaging Tax guidelines for tax exemption and is OPRL compliant for front-of-store drop-off. All virgin material and film used to produce ProActive PIR film are EU food contact grade materials, which comply with Regulation (EU) No 10/2011 and have also undergone additional NIAS testing.
Thought Leadership
On Monday, 8 May, at 11:00 am, Sal Pellingra, the vice president of global package design, applications, and business development at ProAmpac, will be presenting ProAmpac's Approach to Sustainability at the Interpack TV Stage, situated between Halls 7 and 9 at the North Entrance. During the presentation, Sal will highlight sustainable market trends and ProAmpac’s collaborative approach to commercialization of new ProActive Sustainability® technologies toward a more circular economy.
To set up a meeting during the show or learn how ProAmpac’s team can help you, please contact Events@ProAmpac.com or visit ProAmpac.com.
About ProAmpac
ProAmpac is a leading global flexible packaging company with a comprehensive product offering, providing creative packaging solutions, industry-leading customer service and award-winning innovation to a diverse global marketplace. ProAmpac’s approach to sustainability – ProActive Sustainability® – provides innovative sustainable flexible packaging products to help our customers achieve their sustainability goals. We are guided in our work by five core values that are the basis for our success: Integrity, Intensity, Innovation, Involvement and Impact. Cincinnati-based ProAmpac is owned by Pritzker Private Capital along with management and co-investors. For more information, visit ProAmpac.com or contact Media@ProAmpac.com.
About Pritzker Private Capital
Pritzker Private Capital partners with middle-market companies based in North America with leading positions in the manufactured products and services sectors. The firm's differentiated, long duration capital base allows for efficient decision-making, broad flexibility with transaction structure and investment horizon, and alignment with all stakeholders. Pritzker Private Capital builds businesses for the long term and is an ideal partner for entrepreneur- and family-owned companies. Pritzker Private Capital is a signatory to the United Nations Principles for Responsible Investment (PRI). For more information, visit PPCPartners.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230501005442/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom